Canine IL-36 Receptor Antagonist (IL-36RA) ELISA

The Canine IL-36RA ELISA contains capture antibody, standard, and detection antibody for development of a Canine IL-36RA ELISA. The antibodies have been determined to function in an ELISA with the standard provided. Optimal buffers, concentrations, incubation times, incubation temperatures, and methods for the ELISA have not been determined. A working knowledge of ELISA is strongly recommended. The quantities of components provided are not matched. Components may also be purchased separately. For research use only.

Product Specifications

Background

Interleukin 36, or IL-36, is a group of cytokines in the IL-1 family with pro-inflammatory effects. There are four members of the IL-36 family which bind to the IL-36 receptor (IL1RL2/IL-1Rrp2/IL-36 receptor dimer) with varying affinities. IL36A, IL36B, and IL36G are IL-36 receptor agonists. IL36RA is an IL-36 receptor antagonist, inhibiting IL-36R signaling. The agonists are known to activate NF-κB and mitogen-activated protein kinases to induce various proinflammatory mediators. Binding of the IL-36R agonists to IL-1Rp2 recruits IL-1RAcP, activating the signaling pathway. IL-36Ra binds to IL-36R, preventing the recruitment of IL-1RAcP. IL-36 has been found to activate T cell proliferation and release of IL-2. Due to their predominant expression in epithelial tissues, IL-36 cytokines are believed to play a significant role in the pathogenesis of skin diseases, especially that of psoriasis. IL-36 has also been linked to psoriatic arthritis, systemic lupus erythematosus, inflammatory bowel disease, ulcerative colitis, Crohn's disease, and Sjoegren's syndrome. IL-36 is expressed by many cells types, most predominately keratinocytes, respiratory epithelium, various nervous tissue, and monocytes.